What is the clinical significance of the long-term results from the EPCORE NHL-2 trial of epcoritamab + R-CHOP for previously untreated high-risk DLBCL?
During the 18th International Conference on Malignant Lymphomas (ICML), Jun 17–21, 2025, Lugano, CH, the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine at Mount ...
19 Kesä 20254min
EHA 2025 | What are the latest updates from the STARGLO trial of Glofit-GemOx vs R-GemOx in R/R DLBCL?
This educational resource is independently supported by Roche. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of th...
18 Kesä 20254min
EHA 2025 | How effective is epcoritamab + R-ICE in patients with R/R DLBCL who are eligible for ASCT?
This educational resource is independently supported by AbbVie. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of t...
17 Kesä 20254min
Real-world experience of tafasitamab and lenalidomide for the treatment of R/R DLBCL
The Lymphoma Hub was pleased to speak to Grzegorz S. Nowakowski, Mayo Clinic, Rochester, US, who discussed the real-world experience of tafasitamab and lenalidomide for the treatment of relapsed/refra...
2 Kesä 20258min
How effective is the combination of tafasitamab and lenalidomide in treating R/R DLBCL?
This educational resource is independently supported by Incyte. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of t...
30 Touko 202514min
inMIND trial: Tafasitamab plus lenalidomide and rituximab for R/R FL
During the 66th American Society of Hematology (ASH) Meeting and Exposition, the Lymphoma Hub was pleased to speak to Stefano Luminari, University of Modena and Reggio Emilia, Modena, IT. We asked abo...
1 Huhti 20256min
Symposium | Optimizing outcomes before and after CAR T-cell therapy in patients with large B-cell lymphoma
During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint satellite symposium entitled: Sequencing immune-based therapies in B-cell ...
12 Elo 202426min
SEQUOIA trial: Zanubrutinib + venetoclax in treatment-naïve patients with CLL/SLL
During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub was pleased to speak to Paolo Ghia, Vita-Salute San Raffaele, Milan, IT. We asked about the latest updates from ...
12 Elo 20244min
